Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Protein Arginine Methyltransferase 1 (PRMT1) Suppresses The Differentiation of Germinal Centre B Cells and B Cell Lymphoma
FY 2021-22
Summary
Our natural defence against disease-causing germs is known as the immune system. The immune system is constantly protecting our bodies from disease-causing agents such as bacteria and viruses. To fight disease-causing agents, the immune system produces molecules called antibodies. Antibodies specifically recognize germs to stop them from causing disease. The production of antibodies is carried out by a group of cells called B cells. B cells function as tiny antibody-producing factories, constantly generating antibodies that can bind and eliminate germs before they make us sick.
The gene, PRMT1protein arginine methyltransferase 1is a mediator of antibody production. PRMT1 controls the activity of our cells by modifying the chemical structure of cellular molecules. PRMT1 is known to help B cells release antibodies against germs. However, the mechanism by which PRMT1 acts within B cells is unclear. Recently, PRMT1 was shown to be deregulated in B cell cancersa disease in which B cells divide uncontrollably and cause damage to our bodies. Importantly, the de-regulation of PRMT1 in B cell cancers is associated with poor clinical outcomes. Yet, the role of PRMT1 in B cell cancers is poorly studied. Thus, how PRMT1 functions in B cells under normal and diseased states requires further investigation.
This project aims to determine the function of PRMT1 in B cells under normal and diseased states using advanced techniques in molecular biology and immunology. This project will illuminate the role of PRMT1 to antibody-mediated immunity. Furthermore, this research project will reveal the role of PRMT1 in cancers arising from B cells themselves and will rationalize the use of therapies that specifically target PRMT1to treat B cell cancers.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466516
Name
Slattery Michael
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Protein Arginine Methyltransferase 1 (PRMT1) Suppresses The Differentiation of Germinal Centre B Cells and B Cell Lymphoma
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibodies; B Cells; Cancer; Cancer Treatment; Immunity; Infection; Lymphoma
Abstract
Our natural defence against disease-causing germs is known as the immune system. The immune system is constantly protecting our bodies from disease-causing agents such as bacteria and viruses. To fight disease-causing agents, the immune system produces molecules called antibodies. Antibodies specifically recognize germs to stop them from causing disease. The production of antibodies is carried out by a group of cells called B cells. B cells function as tiny antibody-producing factories, constantly generating antibodies that can bind and eliminate germs before they make us sick.
The gene, PRMT1protein arginine methyltransferase 1is a mediator of antibody production. PRMT1 controls the activity of our cells by modifying the chemical structure of cellular molecules. PRMT1 is known to help B cells release antibodies against germs. However, the mechanism by which PRMT1 acts within B cells is unclear. Recently, PRMT1 was shown to be deregulated in B cell cancersa disease in which B cells divide uncontrollably and cause damage to our bodies. Importantly, the de-regulation of PRMT1 in B cell cancers is associated with poor clinical outcomes. Yet, the role of PRMT1 in B cell cancers is poorly studied. Thus, how PRMT1 functions in B cells under normal and diseased states requires further investigation.
This project aims to determine the function of PRMT1 in B cells under normal and diseased states using advanced techniques in molecular biology and immunology. This project will illuminate the role of PRMT1 to antibody-mediated immunity. Furthermore, this research project will reveal the role of PRMT1 in cancers arising from B cells themselves and will rationalize the use of therapies that specifically target PRMT1to treat B cell cancers.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Slattery, Michael
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~